Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patientsMasaki Shiota, Sadafumi Kawamura, Yasuhiro Hashimoto et al.|Cancer Science|2020Cited by 48
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito et al.|BJUI Compass|2020Cited by 19
Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura et al.|Cancer Science|2021Cited by 15
Sequential Therapy with Docetaxel and Cabazitaxel Starting at Low PSA Levels was Associated with Longer Survival in Patients with Castration-Resistant Prostate CancerNaoki Terada, Toshiyuki Kamoto, Atsuro Sawada et al.|Research Square|2021Cited by 0
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancerTokiyoshi Tanegashima, Masaki Shiota, Naoki Terada et al.|International Journal of Clinical Oncology|2024Cited by 0